Calcium channel blockers are a class of drugs that inhibit L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and decreasing contractility, conduction, and vascular tone. They are widely used for hypertension, angina pectoris, and certain cardiac arrhythmias. The two major subclasses, dihydropyridines and non-dihydropyridines, differ substantially in their tissue selectivity and clinical applications.
What Are Calcium Channel Blockers?
L-type calcium channels are voltage-gated channels that open during membrane depolarization, allowing calcium ions to enter cells. In vascular smooth muscle, calcium influx triggers contraction, while in cardiac tissue it contributes to pacemaker activity, conduction through the atrioventricular node, and myocardial contractility. Calcium channel blockers bind to the alpha-1 subunit of these channels, stabilizing the inactive state and reducing the number of channels available to open during depolarization.
Mechanism of Action
By reducing calcium entry into cells, calcium channel blockers produce three primary effects: vasodilation, negative inotropy, and negative chronotropy. The relative contribution of each effect depends on the specific agent. Dihydropyridines such as amlodipine and nifedipine have greater affinity for vascular L-type channels and produce predominantly vasodilation with minimal direct cardiac effects. Non-dihydropyridines such as verapamil and diltiazem have more balanced effects on cardiac and vascular channels, with significant negative chronotropic and dromotropic effects that make them useful for rate control in arrhythmias.
Therapeutic Uses
Calcium channel blockers are effective antihypertensive agents, particularly in older patients and those of African ancestry, who tend to have lower renin levels. They are first-line therapy for stable angina, reducing myocardial oxygen demand through afterload reduction and improving coronary blood flow through vasodilation. Verapamil and diltiazem control ventricular rate in atrial fibrillation and flutter. Non-dihydropyridines are also used for supraventricular tachycardia termination and prevention.
Adverse Effects
Dihydropyridine-associated vasodilation commonly causes peripheral edema, headache, flushing, and dizziness. Reflex tachycardia can occur, particularly with short-acting agents such as immediate-release nifedipine. Non-dihydropyridine calcium channel blockers produce more cardiac effects, including bradycardia, atrioventricular block, and heart failure exacerbation in patients with reduced systolic function. Constipation is a frequent complaint with verapamil. Gingival hyperplasia occurs with long-term use of certain agents.
Contraindications
Non-dihydropyridine calcium channel blockers are contraindicated in patients with sick sinus syndrome, high-grade atrioventricular block without a pacemaker, and severe left ventricular dysfunction. They should be avoided or used with extreme caution in combination with beta-blockers due to additive negative chronotropic effects. Short-acting dihydropyridines are contraindicated in unstable angina and acute myocardial infarction due to reflex tachycardia risks. Calcium channel blockers should generally be avoided in heart failure with reduced ejection fraction.
Conclusion
Calcium channel blockers offer valuable therapeutic options for cardiovascular disease, with the choice between dihydropyridine and non-dihydropyridine agents guided by the specific clinical indication and patient characteristics. Their well-established efficacy and safety profiles make them enduring components of cardiovascular pharmacotherapy.
